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The Ras-Raf-MAPK pathway regulates diverse physiological processes by transmitting signals from membrane based receptors to various
nuclear, cytoplasmic and membrane-bound targets, coordinating a large variety of cellular responses. Function of Raf family kinases has been
shown to play a role during organism development, cell cycle regulation, cell proliferation and differentiation, cell survival and apoptosis and
many other cellular and physiological processes. Aberrations along the Ras-Raf-MAPK pathway play an integral role in various biological
processes concerning human health and disease. Overexpression or activation of the pathway components is a common indicator in proliferative
diseases such as cancer and contributes to tumor initiation, progression and metastasis. In this review, we focus on the physiological roles of Raf
kinases in normal and disease conditions, specifically cancer, and the current thoughts on Raf regulation.
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The receptor tyrosine kinase effector, Raf, named for Rapidly
Accelerated Fibrosarcoma, was discovered over two decades
ago by two groups independently as a retroviral oncogene, v-Raf
[1] or v-MIL [2], possessing a serine/threonine kinase activity
[3–5]. This serine/threonine kinase was later found to function in
the linear Ras-Raf-MEK-ERK mitogen activated protein kinase
(MAPK) pathway [6]. The current view of Raf regulation,
however, ensuing two decades of research dedicated to the
elucidation of the molecular mechanisms of this process, has
grown from this simple linear signaling pathway to a much more
complex one [7–11]. This intricate regulation, which our
appreciation of its complexity increases continuously, involves
various post-translational modifications, protein–protein inter-
actions and cross-talk and feedback mechanisms (see also the
reviews by Kyriakis and Galmiche in this issue).
There are three known mammalian Raf isoforms: A, B and
C-Raf also called Raf-1 or c-Raf-1 (based on the referees
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doi:10.1016/j.bbamcr.2007.05.001we refer in the remaining text to Raf-1/c-Raf-1 as C-Raf) [12].
The majority of the past research has focused on C-Raf, being
the first to be identified and a ubiquitously expressed isoform.
The Raf proteins are structurally conserved from metazoans to
mammals (Fig. 1) [9] as is the Ras-Raf-MEK-ERK signaling
module in general. Our knowledge of Raf function and
regulation comes from the combined efforts of primarily
biochemical studies in mammalian systems and genetic
approaches in metazoans. Many of the initial studies focused
on the role of Raf as a potential oncogene and its role in cancer;
however, the more recent expansion in Raf research, utilizing
diverse model systems such as transgenic and knockout animals
or various cell models, combined with physiological studies in
specific organ systems, have provided clues also on the
“normal” physiological roles of Raf proteins [13–15].
2. Physiological functions of Raf proteins
Besides their established role in tumorigenesis, Raf proteins
and the MAPK pathway have been shown to play key roles in
various “normal” physiological processes as diverse as cellular
metabolism, cell cycle progression, cell death and neurological
function (Fig. 2). Much of our understanding of Raf function
comes from studies using cell culture models, with their obvious
Fig. 1. Structural alignment of Raf isoforms. The human C-Raf (Raf-1 or c-Raf-1), B-Raf and A-Raf are aligned with the Drosophila Raf (D-Raf) and C. elegans
Raf (lin45). Indicated are the positions of conserved regions (CR) 1, 2 and 3, the Ras binding domain (RBD), the zinc finger/cysteine rich domain (CRD) and the
kinase domain. In addition, indicated are the known phosphorylation sites on C-Raf and their corresponding sites in the other Raf isoforms, position of the ATP
binding site (K375) and V600 of B-Raf found mutated in cancers.
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transgenic animal models become available [13,15].
2.1. Insights from knockout and transgenic mice models
Knockout studies of individual Raf isoforms in mice point to
their essential and non-overlapping roles during embryo- and
organogenesis, inasmuch as knockout of each of the Raf
isoforms results in a lethal phenotype in most of the examined
mice strains [16–21]. The lack of functional overlap is also
apparent from phenotypic differences among the various Raf
knockout mice during embryogenesis [13,15]. In general, Raf
knockout mice display severe growth retardation of up to 50%
in size and weight in addition to abnormal development of the
liver, vascular and neuronal tissues.
The first C-Raf knockout description, which showed a lethal
phenotype at embryonic day E10.5 to E12.5, expressed low
amounts of an N-terminal truncated C-Raf protein that
maintained some kinase activity, thus complicating the inter-
pretation of the data [18]. In follow up knockout studies where
the C-Raf protein expression was completely abolished, the
mice showed embryonic lethality and poor development of the
placenta, liver, and haematopoietic organs. These studies also
suggested that C-Raf is required to restrain apoptosis during
embryogenesis [20,22]. Interestingly, activation of the MAPK
pathway in whole embryos and cell lines derived from these
knockout embryos appeared normal, though activation inspecific cell types has not been examined. This finding
prompted the authors to suggest that B-Raf could be the one
mediating MAPK activation in this setting and that other C-Raf
targets besides the MAPK pathway may be responsible for the
observed lethal phenotype. Supporting this notion, a “knock in”
mutation in the C-Raf gene that results in decreased kinase
activity did not have a significant phenotype in the mice,
suggesting that C-Raf kinase activity is not crucial for its
function in the murine model [22]. This claim needs further
confirmation, however, since the mutation used in this study,
YY340/341FF, has only a moderate effect on C-Raf kinase
activity [23] and the residual activity may suffice for its
function. A more definitive examination will require a “knock
in” of a mutation that completely abolishes the kinase activity,
for example, a mutation in the ATP binding pocket such as
K375M. In general, since residual expression of incomplete C-
Raf transcripts coding for various C-Raf protein fragments in
the knockout models could significantly affect data interpreta-
tion, it would be highly significant to extensively verify C-Raf
expression in these mice at both the mRNA and protein levels
for absence of any such variants.
As for other Raf isoforms, B-Raf knockouts die in utero by
embryonic day E12.5 displaying vascular and neuronal defects.
Massive hemorrhaging spills into major body cavities due to
apoptotic death of differentiated endothelial cells results in the
death of the mice during mid-gestation [17,19]. In addition,
these mice also show severe neuronal abnormalities [21].
Fig. 2. Known physiological functions of Raf. See text for details.
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intestinal and neurological abnormalities [16]. In the C57 Bl/6
background, the mice die within 7–21 days after birth.
However, this lethal phenotype is reversed in mice outbred
with the 129/OLA genetic background, which survive to
adulthood but display several neurological pathologies. The
phenotypic variance seen with the different mice strains has not
been established yet and is also observed to a lesser extent with
the C-Raf knockouts.
Collectively, these studies suggest that all Raf isoforms are
required for maintaining normal embryogenesis and sustaining
life. However, the question regarding the exact role of each
isoform in embryogenesis remains open. The current data
suggest that the Raf isoforms share both redundant and non-
redundant functions. For example, single Raf knockouts result
in relatively moderate effects on embryonic development until
embryonic day E10.5, suggesting that Raf isoforms can
compensate to some extent for each other until this develop-
mental stage. Supporting this notion, double B-Raf/C-Raf
knockouts display more severe phenotypes than the single
knockouts, resulting in underdeveloped embryos, which grow
into small clumps of cells representing two distinct lineages
resembling the inner cell mass and the trophoblast cells of the
mouse blastocyst [19]. This study also determined the
expression patterns of the three Raf isoforms, showing that all
three isoforms are equally expressed throughout the embryonicdevelopment and in the adult mouse, disavowing previous
observations indicating tissue- and development-specific iso-
form expression patterns. Similar to the above, double knock-
outs of A-Raf and C-Raf hold a more severe phenotype than
either gene alone, with the double knockouts dying by E10.5,
looking small and abnormal [24].
In a more recent study, Galabova-Kovacs et al. [25]
demonstrated using conditional B-Raf and C-Raf knockouts
that B-Raf is required mainly for placenta development,
possibly through controlling VEGF expression, and that it
serves as the main MAPK activator in this organ. C-Raf on the
other hand, appears important for ERK activation in the embryo
proper and also for erythrocyte differentiation. Interestingly, this
work also did not detect a significant reduction in phospho-ERK
levels in embryos lacking B-Raf expression or significant
effects on cell proliferation rates. These findings indicate that
data obtained using mouse embryonic fibroblast regarding the
role of the different Raf isoforms in MAPK activation is not
recapitulated in the whole organism, reputing previous claims
that B-Raf is the sole physiological MAPK activator. Thus,
more detailed examination of the individual roles of the three
Raf isoforms in specific tissues will be required to gain a better
idea regarding the complex functions of each Raf isoform.
In parallel to the knockout studies, genetically modified
transgenic mice were used to examine the role of the Raf-
MAPK pathway activation in embryogenesis and development.
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constitutively active C-Raf form containing a deletion of the
regulatory N-terminal domain, called BXB-Raf resulted in
normal mouse embryogenesis and development. However, both
transgenics developed lung adenocarcinomas. The BXB-Raf
transgenics displayed accelerated tumor development in
comparison to wild-type C-Raf, pointing to a higher oncogenic
potential of the active C-Raf protein [26,27].
Transgenic mice expressing a conditional knock-in of a
constitutively active B-Raf allele (V600EB-Raf, an activating
mutation occurring naturally in human cancers) during
embryogenesis under the control of a Cre/Lox system did not
survive embryo development, with embryos dying at E7.5,
indicating that expression of a constitutively active B-Raf allele
during embryogenesis is lethal [28]. When the Cre/Lox V600EB-
Raf mice were bred to induce B-Raf expression under the
control of an IFN-inducible promoter, the mice survived
embryogenesis but died before reaching 4 weeks of age.
Thus, even at low conditional V600EB-Raf knock-in levels the
effect was lethal. The transgenic mice showed expression of the
transgene in various tissues including spleen, liver, lung, heart
and kidney, which correlated with increased B-Raf kinase
activity in these tissues. Though the cause of death was not
provided, the mice displayed several hyperproliferative and
developmental abnormalities. For example, the spleen was
greatly enlarged, the liver showed both hyperproliferation and
increased apoptotic regions and the bone marrow had
diminished expression of erythrocytes. There were no apparent
developmental defects in the lung, heart or kidney. Interestingly,
though V600EB-Raf expression and increased B-Raf activity
were detected in the lung and thymus, there was no increase in
ERK phosphorylation. In contrast, both spleen and liver
displayed a significant increase in ERK phosphorylation.
Thus, there appeared to be a correlation between the
pathological effects and the level of ERK phosphorylation
induction. MEF cells derived from the V600EB-Raf Cre/Lox
mice induced to express the mutant B-Raf allele by transfection
of Cre displayed increased proliferation and some character-
istics of cell transformation, such as the loss of contact
inhibition and the ability to form colonies in soft agar. Thus,
expression of an active B-Raf allele from the intrinsic locus can
cause hyper-proliferation and induce transformed characteris-
tics in certain cell lineages. It remains to be determined what
controls these cell specific effects, a key question in under-
standing the oncogenic potential of B-Raf. This study did not
examine the expression levels of the mutant B-Raf allele protein
in the various tissues; therefore, it is not known whether some of
the differences observed in these tissues reflected possible
differences in protein expression levels.
2.2. Insights from tissue culture models
In the past 20 years there have been several thousand
publications relating to Raf function using various culture
models, thus we provide here only a sampling of these studies.
Overall, key roles of Raf have been demonstrated in cell
proliferation, differentiation, cell cycle progression, cell survi-val and several other physiological processes (Fig. 2). For
example, using pharmacological inhibitors for Raf and MEK,
several studies demonstrated that blocking the MAPK pathway
attenuates cell cycle progression mainly by arresting cells at the
Go/G1 boundary ([29,10–31] and our unpublished observa-
tion). However, as noted above, the role of individual Raf
isoforms in this process is less clear and may depend on cell
types or developmental stages. As for cell cycle targets, many
have been proposed including cyclin D1 [24], Rb [32] and
CDC25 [33] among others [34].
Regarding cell proliferation, expression of active Raf forms,
either B-Raf or C-Raf, have pro-proliferative effects, inducing
uncontrolled proliferation and transformation, and as noted
above, even at low conditional gene knock-in levels of the
V600EB-Raf mutant allele, transgenic mice display hyper-
proliferative disorders [28,35–37]. As to the role of specific
Raf isoforms in cell proliferation, the data are less straightfor-
ward. For example, in Ras-transformed melanocytes, B-Raf
depletion by siRNA does not block the MEK-ERK pathway or
cell cycle progression [38].
The role of Raf in cell survival and apoptosis is a topic of a
separate review in this issue (Galmiche et al). In general, Raf
proteins are regarded as pro-survival antiapoptotic factors.
These functions can be mediated by both MEK-ERK dependent
pathways, involving Raf kinase activity, and at least for C-Raf,
some of the data points to kinase independent functions
involving regulation of proteins such as ASK-1 [39], MST2
[40,41] and BAD/Bcl family members [42–44]. In addition, a
recent study demonstrated a role of C-Raf in preventing
apoptosis in cardiac myocytes during induced cardiac ischemia
[14,45].
The role of the Raf-MAPK pathway in differentiation was
originally examined in PC12 cells and showed a role both in cell
differentiation and cell proliferation; a distinction that depended
onMAPK activation levels versus its duration [46]. However, in
other cell lines, for example erythroblasts, C-Raf delays
differentiation by inhibiting caspase activation [47]. In
epidermal development, C-Raf activation can induce terminal
differentiation of keratinocytes [48]. However, the specific role
of C-Raf in this process is not clear since epidermis-specific C-
Raf knockout does not affect epidermis architecture or follicle
development [49]. This topic requires more work since the
knockout models suggest a complex role of the three Raf
isoforms in various stages of development and different cell
lineages.
Other reported cellular Raf functions include roles in cell
motility, migration and wound healing [49,50], T cell develop-
ment and anergy [51,52], and B cell development [53].
2.3. Insights from invertebrate studies
Raf homologues were discovered in various organisms such
as invertebrates, birds, bony fish, and amphibians and many of
the initial Raf studies were performed in invertebrates. Whereas
mammals express three isoforms of Raf, invertebrates have only
one Raf isoform resembling the mammalian B-Raf isoform; D-
Raf in Drosophila [54] and Lin-45 in Caenorhabditis elegans
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This lack of redundancy is also evident along the signaling
module as a whole, where only one MEK and ERK are present
in Drosophila. D-Raf was found to have an important role
during Drosophila embryogenesis and several phenotypes
appear in D-Raf knockout flies. Most significant, the fly
embryos fail to differentiate into structured embryos and, like in
mice, display a lethal phenotype. These studies also showed a
role of Raf in determining the dorsal/ventral polarity of the fly
eggs [56–59]. Genetic screens for activating and inactivating
allelic mutations also contributed significantly to the Raf study
field. For example, mutations in the CR1 domain (R217L), now
known for the RasGTP binding domain, showed a decrease in
D-Raf activity and severe morphological disorganization of the
fly eye [60]. As for gaining pathway understanding, studies in
Drosophila identified D-Raf as a downstream target of the
tyrosine kinase receptors Torso and Sevenless, which play an
important role in fly development. These and other Drosophila
EGF receptor (DER) signaling pathways helped in defining the
mammalian pathway known as the EGF receptor-Grb2-SOS-
Ras-Raf pathway [61–63]. In C. elegans, lin-45 was found
downstream of the mammalian homologue of Ras, let60 [55].
These initial genetic studies helped define the role of Raf and
the MAPK pathway.
More recent work helped in identifying other components
that modulate this pathway. Therrien et al. discovered a
potential Raf scaffold protein, kinase suppressor of Ras, KSR
[64] and a connector enhancer of KSR, CNK [65], both
evolutionary conserved and are discussed below in Raf
Regulation.
Besides the role of Ras in Raf activation, other mechan-
istic aspects of Raf regulation are also conserved across
species. For example, C-Raf phosphorylation at a S338 site
by PAK is conserved in Drosophila, though Lin-45 holds a
histidine at this site (Fig. 1). Also, two potential C-Raf
activating phosphorylation sites, T491 and S494 have
homologues in lin-45 and their substitution with aspartic
acids results in a multi-vulval phenotype, indicating activation
of the MAPK pathway [66].
2.4. Physiological Raf targets and effectors
Both biochemical and genetic studies established a linear
phosphorylation cascade downstream of Raf where Raf
phosphorylates and activates MEK-1/2 that in turn phosphor-
ylates and activates ERK-1/2 [6]. This initial view of Raf
function has been repeatedly contested, however, with the
identification of so called MEK-independent Raf functions in
the past 6–8 years [41,67]. Interestingly, some of the attributed
Raf functions are proposed to be independent of kinase
activity, proposing scaffold and/or structural modulator func-
tions for Raf [15,39,40] (for a recent review, see Galmiche et
al. in this issue). Many of the MEK-independent Raf functions
were determined in experiments using MEK inhibitors or Raf
mutants that abrogate kinase activity. Only a very few studies
identified Raf targets other than MEK. Among the emerging
new Raf targets are proteins involved in programmed celldeath control such as ASK-1 [39] and MST-2 [40], proteins
involved in cell cycle regulation such as RB [32] and Cdc25
[33], cell survival, e.g., NFKB [68] and BAD/Bcl family
members [42–44], and proteins involved in cytoskeletal
organization such as vimentin [69], Rokα [49] and keratin 8
[70]. Though some of these studies provide solid evidence in
cell culture models, their relevance in more physiological
contexts is yet unknown. In addition, the exact role of Raf in
regulating these targets and the associated mechanisms remain
to be determined. Thus, awaiting further confirmation of MEK
independent Raf functions, MEK remains the only well
established physiological Raf target.
3. Role of Raf in cancer
Since its first isolation as a potential cellular oncogene, many
studies involving Raf were focused on its role in cancer [10].
These included examining both its direct role in cancer and its
involvement in mediating transformation by its upstream
effectors, especially Ras and growth factor receptors. Here we
summarize the current literature addressing these two distinct
functions by referring mainly to C-Raf and B-Raf. Though C-
Raf was the first Raf isoform identified as a potential cellular
oncogene, the evidence to support its role as a prime oncogene,
driving transformation, has not been forthcoming. This is
apparent from the lack of identified activating C-Raf mutations
or its aberrant expression in cancer. B-Raf, on the other hand,
has been established in the past 3–5 years as a de facto
oncogene and activating mutations in the gene are highly
prevalent in several human cancers [10,38,71]. Nevertheless, C-
Raf remains an attractive therapeutic target in cancer due to its
role in mediating transformation downstream of oncogenic Ras
and various growth factor receptors. Thus, agents targeting the
Raf family as a whole or C-Raf exclusively have been
extensively examined in many pre-clinical studies and more
recently also in clinical trials [11,72–74].
3.1. Role of C-Raf as a prime oncogene
The only naturally occurring transforming form of C-Raf
described so far is a viral-transmitted form that has a deletion at
the N-terminal regulatory region, resulting in a constitutively
active kinase [1,3,4]. This form can transform NIH 3T3 and
other cell lines in culture, resulting in various cancerous
phenotypes and the ability to form tumors in nude mice. It also
induces tumor formation when expressed in transgenic animals
[10,26,27,75,76]. Other mutations, including point mutations
that result in a constitutive kinase also display transforming
activity in cell culture models, however, to date, these mutations
have not been identified in primary cancers [10,77–79]. Thus,
C-Raf has not been considered as a de facto cellular oncogene.
This notion has been somewhat questioned recently with the
identification of several naturally occurring C-Raf mutations
showing elevated kinase and transforming activity (e.g.,
E478K, S427G and I448V) [78,80]. However, further examina-
tion as to the prevalence of these mutations in human cancers
and determining their role in the tumorigenic process is
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and excluding the possibility of allelic alternations or random
mutations.
Besides activating mutations, attention has been given also
to the expression status of the wildtype C-Raf form. The initial
studies were unable to demonstrate C-Raf activation or
transforming activity as a result of its overexpression in a
variety of cell culture models [36]. However, more recent
studies targeting C-Raf overexpression to the lung demonstrated
its transforming potential, suggesting that under certain
circumstances C-Raf overexpression can display a tumor
promoting or initiating potential [26,27,75]. Providing physio-
logical relevance to these studies, C-Raf has been found
overexpressed in a variety of primary human cancers, such as
lung, liver, prostate, primitive neuroectodermal tumors, myeloid
leukemia and head and neck squamous cell carcinoma [75,81–
85]. Also here, a more thorough examination of C-Raf
expression status in human cancers and its role in the
oncogenesis process is needed to determine the true significance
of these initial observations.
3.2. Role of C-Raf in mediating Ras, growth factor receptor
and other oncogenes effects
In contrast to the uncertainty regarding the role of C-Raf as a
prime oncogene, its significance in mediating oncogenic signals
in a large number of human cancers is well established [6,86–
95]. Being the primary target downstream of Ras, which is
found mutated in up to 30% of all human cancers, the key role
of C-Raf in human cancer is readily evident. This role has been
established in studies using a variety of agents that block C-Raf
function or expression (e.g., anti-sense RNA, small interfering
RNA and small molecule kinase inhibitors), demonstrating
reversal of the transformed phenotype induced by oncogenic
Ras [6,86,91,92,96–101]. In addition, the role of Raf in
mediating Ras-induced transformation was demonstrated in
studies using Ras mutants that bind exclusively to Raf proteins
[91].
Besides its role in mediating oncogenic Ras effects, many
studies established a role of C-Raf also in mediating the
transforming effects of a variety of active growth factor
receptors, oncogenes and mitogens [86,94,102,103]. For
example, C-Raf was found to be the predominant Raf isoform
mediating growth factor-stimulated proliferation in a large
panel of ovarian cancer cell lines [94] and a dominant negative
C-Raf mutant was shown to prevent v-Src-induced transfor-
mation [104]. C-Raf was also shown to cooperate with other
oncogenes such as v-myc and v-Ras in cell transformation, as
well as in cases involving deregulated tumor suppressor gene
expression, such as p53 and RB [32,96,105,106]. In addition,
several recent studies suggest that some of the effects of
activating/oncogenic B-Raf mutations could be mediated
through C-Raf [107,108].
C-Raf has been implied also in cell invasion. A recent study
demonstrated that metastatic prostate cancer cell lines have
decreased expression of the Raf inhibitor protein RKIP, a
protein that attenuates C-Raf/MEK interaction. These cellsdisplayed elevated activation of ERK, which correlated with
increased tumor invasiveness [109,110]. This phenomenon has
also been recently observed in hepatomas [111].
3.3. Role of B-Raf as a prime oncogene
As mentioned above, B-Raf has been the second Raf
isoform to be identified and since in contrast to the ubiquitous
C-Raf expression was considered initially to be mainly a brain
specific isoform, much of the early research focus has been on
C-Raf. This focus shifted however to some degree with the
identification of B-Raf in 2002 as a mutational target in various
human cancers [9,37,71,112]. As of now, B-Raf mutations have
been detected in 70% of melanomas, 30% of thyroid cancers,
15% of colon cancers and at lower frequencies in several other
cancer types [9,28,78]. Most of the mutations were identified
within the kinase domain, with a single amino acid substitution,
V600E, accounting for up to 90% of the mutations. This
mutation results in a constitutive activation of the kinase
domain and correlates in vivo with constitutive activation of its
downstream targets MEK and ERK (both in experimental
models and pathological cancer samples) [38,71,113]. Inter-
estingly, it appears that one hit to the MAPK pathway is
enough for oncogenesis since the current data show very little
overlap of B-Raf and Ras activating mutations in cancer
samples. For example, a recent study in colorectal cancers
found 36% B-Raf mutations and 18% Ras mutations, yet each
mutation occurred exclusively [114]. Similarly, in 21 gall-
bladder carcinoma specimens examined by PCR the B-Raf
activating mutation occurred without the Ras mutation and vise
versa [115].
Interestingly, a corresponding mutation to B-Raf V600E was
not detected in C-Raf or A-Raf in human cancers. This is most
likely due to the fact that C-Raf and A-Raf hold a tighter
regulation of their kinase domain than B-Raf, thus, a single
mutation is insufficient for a substantial kinase activation
[78,79,116,117]. As elaborated below, C-Raf activation requires
phosphorylation at serine 338/339 and tyrosine 340/341 at the
aminoterminal region of the kinase domain, whereas in B-Raf
the comparable serine residue at 445 holds constitutive
phosphorylation and residues 448/449 hold phosphomimetic
aspartic acids, priming B-Raf for activation. A-Raf appears to
be regulated in a similar fashion as C-Raf.
Regarding the transforming effects of B-Raf mutations, the
opinions vary to some extent. Some of the data indicate a strong
oncogenic activity [28,37,38,118], however, the identification of
B-Raf mutations also in pre-malignant lesions, such as benign
nevi [113,118,119], points to the possibility that B-Raf mutations
may be insufficient by themselves to drive transformation and that
other cooperating alternations have to occur for a fully
transformed phenotype.
The involvement of B-Raf in mediating oncogenic signals
downstream of active Ras or growth factor receptors has not
been sufficiently examined yet. However, several initial studies
point to a more dominant role of C-Raf than B-Raf in these
systems [94,95,101]. More detailed examination of various
cancer types and models will be required to get a better
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implications in cancer treatment and future drug development.
3.4. Therapeutics targeting Raf inhibition
This topic has been covered recently in several excellent
reviews [11,72,73,98]. Shortly, several approaches have been
undertaken through the years for achieving Raf inhibition.
These included targeting the Raf kinase activity using small
molecule inhibitors, targeting Raf expression using RNAi and
antisense RNA molecules, and targeting the Ras–Raf interac-
tion. Of the small molecule inhibitors, BAY 43-9006 (Sor-
afenib) is now under advanced clinical trials [93,120]. Another
small molecule Raf inhibitor, SB-590885 has been recently
reported from GlaxoSmithKline, however, its potency in a
whole organism remains to be evaluated [31]. As for BAY 43-
9006, crystallography data indicate its binding to the B-Raf
kinase domain and stabilization of the inactive conformation
[107]. As regards to the biological functions of BAY 43-9006,
not all of its in vivo effects are attributed to Raf inhibition, since
it also inhibits the VEGF and PDGF receptor families. Thus,
some of the anti-tumor effects may be mediated through
inhibition of angiogenesis and tumor vascularization. Phase I/II
clinical trials established the maximum tolerated dose at
400 mg/kg/day of continuous dosing and demonstrated a
potential for disease stabilization and tumor shrinkage in
patients with advanced kidney cancer [120–122]. Currently,
combination trails are underway using BAY 43-9006 with
carboplatin, paclitaxel and other chemotherapeutic agents,
including a Phase III trial for advanced melanoma.
Regarding the targeting of Raf expression, various antisense
and RNAi compounds have been examined. For example, ISIS
5132 which is a 20-base phosphorothioate oligonucleotide
antisense RNA for human C-Raf showed efficient tumor
inhibition in animal models and in several past trials also
some disease stabilization in ovarian carcinoma [123]. More
recent Phase II trials, however, showed no benefit when given
as a single agent. These trials included epithelial ovarian cancers
[124], colorectal carcinoma [125], small-cell lung cancer
(SCLC) or non-small cell lung cancer (NSCLC) [126], and
hormone-refractory prostate cancer [127]. It is likely that future
cancer therapeutic strategies will combine one or more
molecular targeting agents such as ISIS 5132 with conventional
chemotherapies to improve patient outcome. In general, a
significant shortfall in the above studies was that many of them
did not examine patient tumors for MAPK pathway activation,
before and after treatment. Therefore, there is no knowledge of
whether the administered drug actually targeted Raf or the
MAPK pathway.
The success in developing drugs targeting Ras–Raf interac-
tion has been very limited and no clinical data are currently
available.Fig. 3. Raf structure and sequence alignment of human Raf isoforms. (A) Sequen
β-sheets and α-helices, aminoacid identities (boxed, red), aminoacid identities (boxed
structures. Indicated are the positions of the RBD, CRD, kinase domain and of
phosphorylate them are also indicated. See text for more details.4. Raf regulation
We provide here an overview of the current working model
of Raf regulation while emphasizing recent developments in the
field, focusing on Raf phosphorylation and highlighting the
remaining open questions. We direct the reader also to several
recent excellent reviews focused on Raf regulation [8–
11,128,129].
As noted above, the three mammalian Raf isoforms share
structural homology but also display significant variations, both
structural and functional (Figs. 1 and 3). Most of our
understanding of Raf regulation comes from studies using C-
Raf, though several fundamental studies using B-Raf have also
provided significant input to our view of this complex process.
C-Raf is a 648 amino acid protein migrating on SDS/PAGE as a
∼75 kDa polypeptide. There are several regions conserved
among all Raf proteins designated CR1, CR2, and CR3 (Fig. 1).
CR1 contains elements required for Raf membrane recruitment.
In particular, the Ras binding domain (RBD, AA51–149) that
binds to the active Ras-GTP, and a zinc finger structure
homologous to the zinc fingers of PKCs (AA139–184), also
known as the cysteine rich domain (CRD). The CRD region
stabilizes the association with Ras through interaction with a
lipid moiety present on processed Ras [8,9,130–137]. CR2
holds a conserved phosphorylation site at S259 that serves as a
regulatory binding site for 14-3-3 proteins. CR3 contains the
catalytic portion holding the Raf kinase domain and a conserved
serine at S621 that serves as a second binding site for 14-3-3
[8,138]. The transforming v-Raf form (described above)
contains a deletion of CR1 and CR2, resulting in a
constitutively active form of Raf. Thus, the N-terminal half
of Raf is considered to be a negative regulatory domain
which helps in maintaining Raf in an inactive state in the
absence of stimulation [35,36,139,140]. The common view is
that the catalytic domain of Raf is folded and bound to the N-
terminal regulatory domain. This interaction is stabilized by
the binding of a 14-3-3 dimer (Fig. 4) at two C-Raf
phosphorylated sites, S259 and S621 (and the corresponding
sites on the other Raf isoforms, Fig. 1). Following cell
activation, binding of Ras-GTP to the RBD and CRD
domains interferes with 14-3-3 binding to the S259 site and
enforces conformational changes in C-Raf necessary for its
stable activation [8,9,138,141–144]. It is also suggested that
Ras binding could affect C-Raf structure and expose a
docking site for its substrate, MEK [145]. Adding to this
complexity, the binding of Ras to the Raf zinc finger is
thought to disrupt the intramolecular binding of the zinc
finger to the catalytic domain and commences the initial steps
of Raf activation.
Inasmuch as Ras binding to C-Raf is insufficient by itself for
C-Raf activation [146–148], it is postulated that C-Raf
undergoes further modifications following Ras binding. Thesece alignment of the three human Raf isoforms. Indicated are the positions of
, clear) and known C-Raf phosphorylation sites (green triangles). (B) Known Raf
CR1–3. The known Raf phosphorylation sites and potential kinases that can
Fig. 4. Raf activation model. This is a simplistic model showing the role of Ras, 14-3-3 and potential kinases involved in Raf activation. See text for details.
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does not require continuous association with Ras [8,9]. This
model of Raf activation is supported by findings using the
truncated C-Raf form that lacks the entire N-terminal
regulatory region. Though this truncated Raf has an elevated
basal kinase activity, it remains responsive to growth factor
stimulation, suggesting that complete C-Raf activation also
requires modifications within the kinase domain itself [149–
151]. The large majority of the model above is based on
mutational and functional analyses and thereby should be
viewed with due attention. The available structural data are
for the isolated C-Raf RBD and CRD domains [152–156] and
the B-Raf kinase domain [107]. These structures, however,
allow for only partial prediction of the structure of the full-
length protein. This caveat is of specific significance since
Raf is present in the cell as part of a large protein complex,
which involves homo- and heterodimers of Raf, 14-3-3
proteins, heat shock proteins and others [9,108,128]. Thus,
the effects of these interactions on Raf structure are hard to
predict.
As to the Raf activation process following the interaction
with active Ras, the common thinking is that C-Raf undergoes a
series of phosphorylation and dephosphorylation events that
result in a stably active form [9,129]. This aspect of Raf
regulation turned out to be a highly challenging task to tackle
and remains only partially resolved.4.1. Raf regulation by phosphorylation
As noted above, most of the studies regarding Raf regulation
have been done with C-Raf, thus we use here the numbering of
C-Raf in referencing the known phosphorylation sites. In
resting cells, C-Raf is inactive and is found phosphorylated at
several sites, considered to be the basal C-Raf phosphorylation
sites. These sites include S43, S259, S621 and several other
sites that remain to be identified [142,151,157–159]. S259 and
S621 phosphorylations serve for generating binding sites for 14-
3-3 [138,150] and S43 is thought to be a negative regulatory site
targeted by PKA [160–162]. Following cell stimulation with
growth factors, C-Raf is activated, concomitant with its
increased phosphorylation. These phosphorylations are
believed to maintain the active C-Raf conformation, since
treatment of active C-Raf with phosphatases results in a
complete inactivation of its kinase activity [151,163]. The
identities of some of the growth factor-induced sites have been
established, yet the question remains whether other unidentified
sites can contribute to C-Raf activation.
To date, the major identified catalytically significant,
growth factor-induced C-Raf phosphorylation sites are
located within a region outside the actual catalytic domain
and involve S338/9 and Y340/1 [164–167]. Phosphorylations
at these sites can be mediated by the p21 Rac-activated
kinase family (PAK) and the Src family of tyrosine kinases
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the inhibitory effect of the N-terminal part on the catalytic
domain, stabilizing the active form of C-Raf [140,142,168].
However, this model is somewhat questioned by the fact that
these residues are also required for the activation of the
truncated C-Raf form that lacks the N-terminal regulatory
region [150]. Interestingly, the S338/339 sites are conserved
among most of the known Raf proteins (Fig. 1), with the
exception of A-Raf that has a glycine at the corresponding
S339 site and the C. elegans Raf, Lin-45 that has histidines
at its corresponding sites. The YY340/341 motif has more
variations, with B-Raf, D-Raf and Lin-45 having phospho-
mimetic, charged residues (Glu or Asp) at their corresponding
sites. These differences are believed to prime these kinases
for activation, thus resulting in kinases that require less
activation-related modifications for full activation [9,78,117].
This fact, however, combined with the report that B-Raf
S446 (corresponding to C-Raf S338) is found constitutively
phosphorylated in resting cells, where the kinase is inactive,
suggest that phosphorylation at these sites, though may be an
essential step in the activation process, does not activate Raf
per se. Thus, the activating Raf phosphorylation site(s), if
exist, remains elusive.
A significant breakthrough in understanding Raf kinase
regulation came with the identification of cancer related
mutations in B-Raf [71]. Though many mutations have been
reported thus far, some with holding elevated kinase activity
and others not, the large majority of the mutations were
confined to a single amino acid, V599 (due to an initial
sequencing error, V600 was assumed as V599; more current
literature cites the site as V600, thus we use here the new
nomenclature). The mutations identified in V600 were
substitutions to charged residues, i.e., Glu, Asp or Lys,
resulting in a constitutively active kinase displaying an
oncogenic potential [38,107,169,170]. As noted above,
however, these mutations do not necessarily lead to a full
malignant transformation in humans [113,118,171]. The ability
of the V600E substitution to activate the B-Raf kinase,
combined with data from the kinase domain crystal structure
showing that this mutation forces a conformational change that
allows a more open configuration and potentially a better
access for the substrate, suggest that phosphorylations at
proximal sites to V600 may be responsible for Raf activation
in response to growth factor stimulation under normal
conditions [9,107]. The generality of this proposed activation
mechanism when considering the other Raf isoforms remains
to be determined, especially in light of the fact that activation
of the other isoforms involves a more complex mechanism.
Nevertheless, several phosphorylation sites in close proximity
to B-Raf V600 (V492 in C-Raf) have been reported in both in
B-Raf and in C-Raf (Fig. 1) [66,151,172,173]. These sites
include C-Raf S497/9 [172], two phosphorylation sites that
were identified initially in B-Raf, Thr599 and S602 [173] and
confirmed in C-Raf (T491/S494) [66] and S471, identified
initially in C-Raf [151].
S497 and S499 were reported as activation sites targeted by
PKC [172], however, this notion has been later challenged [174]and the role of these sites in C-Raf activation by growth factors,
Ras or even TPA appears to be limited [23].
The B-Raf T599/S602 sites were identified by Zhang et al.
[173] and confirmed using phosphospecific antibodies devel-
oped against these sites. These phosphorylations are not present
on B-Raf isolated from resting cells and are induced by RasV12.
Substitution of these sites with alanine results in an inactive
kinase and their substitution with phosphomimetic charged
residues results in a constitutive kinase, implying that these sites
are potential de facto B-Raf activation sites. These sites are also
conserved in C-Raf; however, the data confirming their
phosphorylation or demonstrating a significant role of these
sites in C-Raf regulation is limited [66] and subject to debate
[23]. The physiological regulation and significance of these
sites in vivo, both for B-Raf and C-Raf, remains unknown.
C-Raf S471 was identified by mass spectrometry as a growth
factor-induced C-Raf phosphorylation site and mutational
analysis demonstrated that its substitution with several other
residues; Ala, Cys, Glu or Asp results in an inactive kinase, but
substitution with Thr preserved some of the kinase activity
[151]. Similarly to B-Raf T599/S602 sites, C-Raf S471 is
conserved among all known Rafs except Lin-45 that has a Thr at
its corresponding site (T605, Fig. 1). Mutations of the
corresponding sites in B-Raf or Bxb-Raf also resulted in
inactive kinases that were unresponsive to growth factor
activation. Importantly, this inactivation was restored in B-Raf
by the V600E substitution, suggesting that phosphorylation at
this site is important for growth factor induced Raf activation
but is dispensable when V600 contains a charged residue.
Thus, both of the above studies imply that phosphorylation
within this CR3 region is important for Raf activation.
However, more evidence supporting the identity of these
phosphorylation sites and the identification of a kinase(s)
responsible for their phosphorylation, capable of Raf activation
is needed to fully establish their role in Raf regulation.
Furthermore, the physiological roles of these phosphorylations
under normal and transformed conditions remain to be
examined.
In addition to the search for activating Raf phosphorylation
sites, several reports recently described regulatory Raf phos-
phorylation sites that, while not directly affecting the catalytic
activity of Raf, participate in Raf regulation by affecting its
inactivation rate [158,159,175]. Albeit these sites were
described and confirmed independently by several groups, the
functional role of these phosphorylations remains controversial.
Combined, these studies reported a total of 5 novel C-Raf
phosphorylation sites: S29 at the N-terminal regulatory region, a
stretch of three phosphorylation sites close to the CR2 region at
S296, S289 and S301, and one at the carboxy-terminal end at
S642 (see Fig. 5 for the location of these sites on a 2D
phosphopeptide map of C-Raf). The common feature of these
sites is having a proline-directed phosphorylation motif. Indeed,
phosphorylation at these sites was shown to be largely mediated
by ERK, which belongs to the proline directed kinase family. As
regards to the functional debate, Dougherty at al [158] and
Hekman et al. [175] ascribe a negative feedback role to these
phosphorylations while Balan et al. [159] claim a positive,
Fig. 5. 2-D C-Raf phosphopeptide map. An example of C-Raf phosphopeptide maps showing the positions of several known C-Raf phosphorylation sites. The identity
of the mutants is indicated. Panel 1 is wildtype C-Raf. For method details see references 151 and 159. Spots 1, 2 and 3 in panel 6 represent pS43, pS621 and pS259
respectively.
1206 D.T. Leicht et al. / Biochimica et Biophysica Acta 1773 (2007) 1196–1212kinase stabilizing role. Establishing the true physiological
significance of these phosphorylations will require a more
detailed examination and the resolution of these conflicting
observations. Importantly, the physiological role of these
phosphorylations appears significant since their phosphoryla-
tion on endogenous C-Raf was induced by growth factors and
during cell cycle progression ([159] and our unpublished
observation). In addition, besides establishing a new mode of
feedback C-Raf regulation, these studies reveal a potential
mechanism for isoform specific Raf regulation, since these sites
are not well conserved among the three-mammalian Raf
isoforms (Figs. 1 and 3). Thus, C-Raf may be uniquely
regulated by ERK-mediated feedback phosphorylation, affect-
ing its activation duration and possibly other functions.
When considering the available literature on the critical role
of phosphorylation in C-Raf activation and in maintaining its
active conformation on one hand and the identified Raf
phosphorylation sites on the other, it is almost inevitable to
assume that there are other as-of-yet unidentified C-Raf
phosphorylation sites that play a role in C-Raf regulation.
Thus, a more comprehensive approach will be required for their
full identification. In addition, it is possible that C-Raf
activation could be achieved via separate modes, involving
different phosphorylation sites. This possibility has been
demonstrated for Raf activation by VEGF and PDGF
[176,177] and for v-Ras and v-Src involving the S338/9 and
Y340/1 sites [23,167]. The large plethora of factors that
activate Raf, including various cytokines, stress factors,
ionizing irradiation, cell cycle state etc., imply that the modesof C-Raf activation may be even more diverse than we
currently contemplate.
Besides the above-mentioned sites, also S233, S268 and
T269 were reported to be C-Raf phosphorylation sites. S233 is
thought to be a negative regulatory site targeted by PKA [95],
while S268 and T269 are presumed to be an autophosphoryla-
tion site and a target site for a ceramide activated kinase or KSR,
respectively [157,178,179]. Also here, the validity of the sites
and their significance in C-Raf regulation, as well as the kinase/
s responsible for their phosphorylation is a subject to debate and
needs further examination.
4.2. Raf regulation by other modes
Besides Raf regulation through phosphorylation, various
protein–protein interactions have been shown to play key roles
in Raf regulation [128,141,180]. These include binding of Raf
to Ras [6] and 14-3-3 proteins [138], Raf homo- [181] and
heterodimerization [108], and association with chaperones such
as HSP-90/p50(cdc37) [182,183] and HSP/HSC-70 [151]. Raf
is also regulated through association with various scaffold
proteins such as KSR [184,185], CNK [65,186], RKIP
[187,188] and others, and possibly through its association
with its target proteins, predominantly MEK (unpublished
observation). These aspects of Raf regulation are covered in
several excellent recent reviews [141,180] and by Kyriakis JM
in this issue.
Surprisingly, after more than 20 years of study, our
knowledge on the regulation of Raf transcription and translation
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recycling and inactivation. For example, Raf degradation has
been proposed to involve a proteasome-mediated pathways
[189–191]. A recent report implicated PP5 in Raf inactiva-
tion by dephosphorylating S338 [192], providing an initial
insight into this process. This aspect of Raf regulation might
turnout to be as complex as the Raf activation process and
will require more intensive examination, both under normal
and disease conditions. Also the question relating to the
regulation of Raf expression is of special importance since,
as mentioned above, C-Raf overexpression in cancer appears
significantly prevalent.
5. Conclusions and future perspectives
During the 20 years since their identification many aspects of
Raf regulation and function have been uncovered, yet many key
questions remain unanswered. These include aspects of isoform
specific Raf functions, understanding Raf function under
physiological conditions and gaining more insight into Raf
regulation, especially its recycling and inactivation. As to
isoform specific functions, in view of the necessity of all three
Raf isoforms for normal organism development, a key and in-
exchangeable role of each isoform is apparent, calling for
unveiling the unique function of each isoform in a physiological
context. Furthermore, it will be important to distinguish whether
the isoform specific functions are merely due to differences in
expression patterns or due to unique functions dictated by
distinct protein attributes. This question can be addressed by
replacing the Raf coding sequence of one isoform with that of a
different one and vise-versa as done recently by Camarero et al.
[193]. In addition, the recent identification of ERK-mediated
phosphorylation sites on C-Raf that are not conserved in B- or
A-Raf, with the potential of these sites serving as feedback
regulation sites, raises the possibility for C-Raf specific
regulation especially in terms of its activation/inactivation
duration.
Many of the studies on Raf and the entire MAPK pathway
have focused on experimental models using acute growth factor
activation (high concentrations for a short time period). These
models do not reflect physiological conditions in the organism,
in which acute growth factor exposures are highly rare events.
Thus, the function of the pathway under “normal” growth
conditions is fairly unknown. Furthermore, one would expect
that these functions would be largely cell type and organ
specific. In this regard, even our understanding of the role of
Raf and the MAPK pathway in a relatively defined biological
setting of cell cycle progression is considerably limited and
even less known are isoform specific Raf functions during this
process.
As regards to the role of Raf in cancer, though B-Raf is
distinguished at present as the principal Raf isoform
associated with human cancer due to the prevalence of its
mutations, these cancer cases overall represent only a small
fraction of human cancers in which Raf may play a key role.
The large majority of cancers that involve increased MAPK
activation do not carry Raf mutations (e.g., cancers withmutant Ras or growth factor activation). Thus, in these
settings it is important to define the relative contribution of
the three Raf isoforms in the tumorigenic process. Thus far,
many of the experimental approaches involved the use of
dominant negative Raf forms that function largely by
inhibiting Ras or MEK and are not informative in determining
the role of Raf in these settings or distinguishing between
isoform specific functions. Similarly, the existing small
molecule Raf inhibitors do not differentiate between the
three Raf isoforms. The main tool to address this question is
the use of RNAi reagents specific for each Raf isoform.
However, even this approach may not provide conclusive
answers when considering the recent reports that C-Raf and
B-Raf could act in concert through heterodimerization, though
the physiological significance of these observations awaits
further confirmation.References
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